

3-15-00

PTO/SB/05 (2/98)

Please type a plus sign (+) inside this box → ☒

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

03/13/00
jc780 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket No.	30008-pa
	First Inventor or Application Identifier	Barry Farris
	Title	Method and Apparatus for the Storage . . .
	Express Mail Label No.	EL298172277US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small> 2. <input checked="" type="checkbox"/> Specification [Total Pages 33] <small>(preferred arrangement set forth below)</small> - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the invention - Brief Summary of the invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 9] 4. Oath or Declaration [Total Pages 1] a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) <small>(for continuation/divisional with Box 17 completed)</small> <small>[Note Box 5 below]</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). 5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies
ACCOMPANYING APPLICATION PARTS	
8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 9. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> * Small Entity Statement filed in prior application, Status still proper and desired 14. <input type="checkbox"/> Statement(s) <input type="checkbox"/> Status still proper and desired <small>(PTO/SB/09-12)</small> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 16. <input type="checkbox"/> Other:	
<small>* NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).</small>	

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit: _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here)

Name	Bernhard Kreten				
Address	77 Cadillac Drive, Suite 245				
City	Sacramento	State	California	Zip Code	95825
Country	United States	Telephone	(916) 921-6181	Fax	(916) 921-9213

Name (Print/Type)	Bernhard Kreten	Registration No. (Attorney/Agent)	27,037
Signature	<i>[Signature]</i>	Date	3/13/2000

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

03/13/00
jc564 U.S. PTO
09/524213

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

Applicant: Barry Farris

For: Apparatus and Method for the Storage and Transfer of a Lyophilisate


Paper:

1. Patent Application - utility (comprised of pages 1 through 33);
2. Utility Patent Application transmittal letter;
3. Fee Transmittal (original and one copy);
4. Declaration for Patent Application;
5. Verified Statement Claiming Small Entity Status (independent inventor);
6. Nine (9) sheets of drawing figures (comprised of figures 1-9);
7. PTO 1449 (including prior art copies); and
9. A check in the amount of \$666.00, \$345.00 which reflects the government fee for utility patent application; \$243.00 of which reflects the government fee for 27 claims in excess of 20; and \$78.00 of which reflects the government fee for 2 independent claims in excess of 3.

I hereby certify that the above identified correspondence, which is attached, is being deposited with the **United States Postal Express Mail, Post Office to Addressee, mailing label EL298172277US** in an envelope addressed to:

Assistant Commissioner for Patents, Box Patent Application, Washington DC 20231

on March 13, 2000.

Ellen J. Tenud

(Signature)
March 13, 2000
(Date of Signature)

Applicant or Patentee: Barry Farris
Serial or Patent No.: _____ Attorney's Docket No.: 30008-pa
Filed: HERE WITH
For: Method and Apparatus for the Storage and Transfer of a Lyophilisate

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) and 1.27(b)) - INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41 (a) and (b) of Title 35, United States Code, to the Patent and Trademark described in:

XX the specification filed herewith.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign grant, convey or license any rights in the invention is listed below:

XX no such person, concern, or organization.
_____ person, concerns or organizations listed below*

*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

FULL NAME _____
ADDRESS _____
[] individual [] small business concern [] nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon or any patent to which this verified statement is directed.

<u>Barry Farris</u>		
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
Signature of Inventor	Signature of Inventor	Signature of Inventor
Date	Date	Date

[illegible]

METHOD AND APPARATUS FOR THE STORAGE AND TRANSFER OF A LYOPHILISATE

FIELD OF THE INVENTION

The following invention relates generally to a method and apparatus for storing a dry substance, activating the substance with liquid and subsequently transferring the substance from storage into a syringe or cannula without the need for a needle. More particularly, the invention relates to a storage container for storing a substance that has undergone a lyophilization process and is ready for the introduction of a liquid to dissolve the lyophilisate into a medium that may be then utilized according to its appropriate prescription. More specifically, the instant invention inhibits the lability of pharmaceuticals.

BACKGROUND OF THE INVENTION

The potency, efficacy, freshness and/or safety of many substances degrade over time. Therefore, manufacturers will usually mark their products with a date of expiration which states explicitly that the contents contained therein will not be as effective, fresh or safe to use subsequent to the date printed on the identification mark. This is of particular concern to pharmaceutical companies dealing with the efficacy of their pharmaceutical products degrading over time, because of many pharmaceuticals' labile nature. This degradation may reach a point where using the particular pharmaceutical product beyond the date imprinted on the bottle could result the pharmaceutical providing no effect, not enough effect or negative effects on persons taking the product as prescribed by the pharmaceutical manufacturer's directions, distributor's directions, seller's directions, product's directions, pharmacy's directions and/or the attending physician's directions.

SUMMARY OF THE INVENTION

The instant invention inhibits the labile nature of substances. In its essence, the instant invention takes advantage of the lyophilic process and provides a container for storing the lyophilisate which in such a state inhibits the lability of pharmaceutical products. This container provides an aseptic environment that prevents bacteria from propagating to the pharmaceutical product and thus potentially effecting the product in an adverse manner.

Further, the instant invention provides for a process that dissolves a powdery substance stored in an ampule. The ampule has a first coupler defining an outlet which has been sealed by occluding the first coupler outlet with a first cap.

A needleless syringe or cannula is configured with a second coupler and an opening which communicates within an interior cylindrical hollow of the syringe so that fluid passes by the second coupler through the opening and into the cylindrical hollow and fills the syringe or cannula. The steps include providing a vial which has been filled with a fluid. The vial has a vial outlet including a third coupler defining the vial outlet and which has been sealed by occluding the third coupler of the vial outlet with a second cap. Subsequently, remove the second cap from the vial and orient the second and third couplers of the syringe or cannula and vial, respectively into complementary, fluid-tight locking engagement so that the opening of the vial registers with the opening of the syringe or cannula. Next, transfer the contents of the vial to the syringe or cannula. This is described in U.S.P. No. 5,716,346. Subsequently, remove the first cap from the ampule and orient the first coupler of the ampule with the second coupler of the syringe or cannula into complementary, fluid-tight locking engagement so that the opening of the ampule

registers with the opening of the syringe or cannula. Next, transfer the fluid of the syringe into the ampule; mix the powdery substance and fluid until the powdery substance is dissolved thus making a mixture preferably while the ampule and syringe or cannula remain mated. Then convey the mixture back into the syringe or cannula and prepare the syringe or cannula for the capability of inserting the mixture into a recipient object.

Further, the instant invention provide for another process for forming an ampule to transfer pharmaceutical grade fluid or solid to be administered. By "fluid" it is meant to include compressible fluid such as gas or liquid as well as pulverulent matter. Solid is defined as compressed or bound together pulverulent material or material embodied as a pill, lozenge, crumbly matter or discrete particles to be dissolved. The process includes: forming an ampule with resilient walls so that the ampule can be collapsed and creating an orifice to introduce the dry pharmaceutical grade fluid or solid; forming an opening on the ampule such that the opening is circumscribed by a coupler which is to be complementally fastened to receive a dose administering device; filling the ampule with the liquid, mixing the liquid with the dry and using.

Further, the instant invention provides for an ampule for storing a pharmaceutical product in a manner to inhibit lability of the product and permitting the transfer of the product in an aseptic manner to avoid nosocomial infection from ambient air. The ampule has resilient walls that can be collapsed and includes an orifice to pass a pharmaceutical grade fluid (as recited in the previous paragraph for example) or solid therethrough and an opening on said ampule whereby the

opening is circumscribed by a coupler which is to be complementally fastened to receive a dose administering device.

Further, the instant invention completely avoids the use of a needle when loading the syringe by extracting fluid from a vial or an ampule. In its essence as such, the instant invention takes advantage of a coupling that is the standard on a majority of syringes which had heretofore only been used in the past to support the hypodermic needle on the syringe. This coupling, called a luer fitting, has a male component and a female component. Typically, the syringe is configured with the "male" luer coupling which appears as a truncated cone that has an opening at its narrowest cross-section some luer couplings are threaded. The luer coupling typically diverges toward an interior cylindrical hollow portion of the syringe. The instant invention replaces the "female" luer coupling and associated needle itself and instead replicates the female coupling on a specially formed ampule or vial so that docking between the ampule or vial and a needleless syringe benefits from the pre-existing male coupling already found on common syringes. Walls of the ampule or vial are flexible to not only promote removal of the fluid therewithin, but to avoid ambient air into the vial or ampule during fluid transfer. Instead of admitting air, the walls collapse.

Further the instant invention may include a filter cartridge having a body with first and second coupling-ends and a filter disposed within the body; whereby the first coupling-end includes a female luer-type tapering for frictional engagement with a needleless syringe or cannula; and whereby the second coupling-end includes a male luer-type tapering for frictional engagement with a female luer-type taper on

a proximal end of a needle, cannula, catheter, etc. Further, the filter cartridge of instant invention can be integral with the ampule of the present invention.

Further the instant invention provides a filtered needle for use with the system of the present invention.

With an opening of the ampule and the opening of the syringe in face-to-face docking registry and in fluidic communication, the ampule can be evacuated by any of a combination of manipulative steps. First, assume the syringe is in its initialized state, with its plunger nested well within the cylindrical hollow of the syringe body so that the plunger is in a compact, retracted state. First the syringe is loaded with liquid, preferably from the vial. Next the syringe feeds the ampule with the vial's liquid for mixing. The contents of the ampule is then retransferred to the syringe (while still docked to the ampule) with none or a minimal, negligible amount of ambient air introduced into the syringe. Deforming the side walls of the ampule and "milking" (i.e. applying hydrostatic force to) the liquid from the ampule and thus into the syringe eliminates air invasion. This causes the plunger of the syringe to translate outside the cylindrical hollow. As the plunger advances out of the cylindrical hollow, liquid enters the syringe.

Another strategy involves manipulation of the plunger to draw the fluid from the ampule by suction so that the arming of the syringe occurs by retracting the plunger to extract the liquid from the ampule without introducing ambient air. As before, the plunger starts well within the syringe and reciprocates outwardly of the cylindrical hollow.

A third strategy is a hybrid of the two previously discussed techniques which involves manipulation of both the ampule by squeezing the ampule and suction by

moving the plunger out of the syringe cylindrical hollow. Thereafter, in all cases the ampule is disconnected from the syringe.

Once the ampule has been removed, a syringe has the intended fluid medication disposed therewithin. Unlike the prior art, no needle has yet been involved. Also, no air from the ambient environment has been mixed with the sterile fluid as was the case with rigid wall vials.

In one form of the invention, it is contemplated that the opening associated with the ampule is provided with a removable cap having a luer-type coupling and an indicia bearing tab. The medicinal contents of the ampule is stamped on the tab for identification purposes. With such an arrangement, it is possible to transfer the cap and tab from the ampule and connect the cap to the syringe to provide a tell tale of the contents of the fluid contained within the syringe. As an alternative, the ampule could remain docked to the syringe until subsequent use. The ampule would also note the contents on a surface thereof.

As a result of this system, the entire process for filling a syringe has been accomplished without the use of a needle. Personnel are able to operate more quickly with less fear of either inadvertent needle stick or inadvertent exposure to the medicine contained within the syringe.

It is to be noted that for many in-patients, the standard procedure in a hospital is to tap into a person's vein only once with an infusion catheter and to leave the catheter needle in place with tubing communicating therewith so that subsequent fluids such as intravenous drips and the like can be used. With such a system, a needle would never be needed with the syringe according to the present invention. "Y" connectors are well known in the art, one branch of which and would have a

complemental female luer coupling. Thus, for a patient's entire stay at a hospital, the only needle associated with that one patient, ideally, would be the one which initially had been placed in the patient's vein to support the infusion catheter. In this way, the opportunity for inadvertent needle sticks would be reduced to a minimum.

OBJECTS OF THE INVENTION

Accordingly, it is an object of the present invention to provide a method and apparatus for transferring sterile fluid from an ampule to a hypodermic syringe after mixing liquid and solids in the ampule without the need of a hypodermic needle.

It is a further object of the present invention to provide a device and method as characterized above which reduces the amount of time which hospital staff must spend in transferring fluid from a sterile ampule to a hypodermic syringe while also eliminating the fear of an inadvertent needle stick thereby avoiding the possibility of both unwanted contamination and unwanted medication.

A further object of the present invention contemplates providing a device and method as characterized above which is extremely inexpensive to fabricate, safe to use and lends itself to mass production techniques.

A further object of the present invention is to provide a device which can reduce the number of times that needles are required in a hospital or other medical setting.

A further object of the present invention contemplates providing a device and method which minimizes the disposal problems of hypodermic syringes with needles.

A further object of the present invention contemplates providing a device and method for use in which a tell tale is associated with first the ampule that stores the medicine, and then the syringe so that the fluid transferred from the ampule and into the syringe will be known at all times. In this way, the chain of custody of the fluid can be more readily monitored.

A further object of the present invention contemplates providing a system for loading syringes that obviates the need for the medicating health professional from having to trundle a miniature pharmacy on a cart from patient to patient. By pre-filling the syringes at a remote location added security and efficiency may be provided.

When viewed from a first vantage point it is an object to provide a needleless dosage transfer system for removing a sterile fluid from a sealed vial to a conventional syringe. The syringe has a plunger such that the plunger of the syringe translates from a first position telescoped within an interior cylindrical hollow of the syringe to a second position where the plunger has been displaced from the interior hollow and replaced by the fluid. The vial is defined by an end, collapsible side walls extending from the end thereby defining a blind bore and having an open end, a coupler at the open end of the vial, and a removable cap occluding the open end at the coupler. The vial coupler is provided with means to connect to a needleless opening of the syringe to be in fluid communication therewith, whereby fluid can be transferred to the syringe from the vial without an interconnecting needle. The syringe then docks with an ampule having the lyophilized material for mixing and subsequent use.

Viewed from a second vantage point, it is an object to provide a method for transferring injectable fluids from a storage vial to a needleless syringe or other device using a male luer fitting. The syringe has a first coupling and an opening which communicates within an interior cylindrical hollow of the syringe so that fluid passes by the first coupling through the opening and into the hollow to load the syringe. The steps include providing a vial filled with fluid and with an outlet

which has a second coupler defining the outlet. The vial is sealed by occluding the coupler outlet with a cap. Subsequently, removing the cap and orienting the first and second couplers into complementary fluid tight docking arrangement (so that the opening of the vial registers with the opening of the syringe) allows transfer of the contents of the vial to the syringe without the need for a traditional needle extraction system. An ampule then docks with the syringe for mixing a lyophilized substance with the syringe fluid.

Viewed from a third vantage point, it is an object to provide a method for forming an ampule to transfer medicine to be infused to a patient. The steps include forming an ampule with resilient walls so that the ampule can be collapsed, forming an opening on the ampule such that the opening is circumscribed by a coupler which is fashioned to receive a dose administering device, loading the ampule with the dry medicine and finally capping the ampule opening.

Viewed from a fourth vantage point, it is an object to provide for a process that dissolves a powdery substance stored in an ampule. The ampule has a coupler defining the outlet and which has been sealed by occluding the coupler outlet with a cap. A needleless syringe or cannula is configured with a coupler and an opening which communicates within an interior cylindrical hollow of the syringe so that fluid passes by the coupler through the opening and into the cylindrical hollow and fills the syringe or cannula. The steps include providing a vial which has been filled with a fluid. The vial has a vial outlet including a coupler defining the vial outlet and which has been sealed by occluding the coupler of the vial outlet with a cap. Subsequently, removing the cap from the vial and orienting the couplers of the syringe or cannula and vial, respectively into complementary, fluid-tight locking

engagement so that the opening of the vial registers with the opening of the syringe or cannula. Next, transfer the contents of the vial to the syringe or cannula. Subsequently, remove the cap from the ampule and orient the coupler of the ampule with the coupler of the syringe or cannula into complementary, fluid-tight locking engagement so that the opening of the ampule registers with the opening of the syringe or cannula. Next, transfer the fluid of the syringe into the ampule; mix the dry substance in the ampule with the fluid from the syringe until the dry substance is dissolved thus making a mixture preferably while the ampule and syringe or cannula remain mated. Then convey the mixture back into the syringe or cannula and prepare the syringe or cannula for the capability of inserting the mixture into an animate or inanimate object. The mixture may be filtered prior to insertion.

Viewed from a fifth vantage point, it is an object to provide for another process for forming an ampule to transfer pharmaceutical grade fluid or solid to be administered. The process including: forming an ampule with resilient walls so that the ampule can be collapsed and creating an orifice to pass the pharmaceutical grade fluid or solid into the ampule and then sealing the orifice; also forming an opening on the ampule and sealing with a cap and a scoreline such that the opening defines a coupler which is to be complementally fastened to and receives a dose administering device.

Viewed from a sixth vantage point, it is an object to provide for an ampule for storing a pharmaceutical product in a manner to inhibit lability of the product and permitting the transfer of the product in an aseptic manner to avoid nosocomial infection from ambient air. The ampule has resilient walls that can be

collapsed and includes an orifice to pass a pharmaceutical grade fluid or solid therethrough and an opening on said ampule whereby the opening defines a coupler which is to be complementally fastened to receive a dose administering device.

Viewed from a seventh vantage point, it is an object to provide a filter cartridge having a body having first and second coupling-ends and a filter disposed therebetween; whereby the first coupling-end includes a female luer-type tapering for frictional engagement with a needleless syringe or cannula; and whereby the second coupling-end includes a male luer-type tapering for frictional engagement with a female luer-type taper such as on a needle or cannula. Further, this filter cartridge of instant invention can be integral with the ampule of the present invention.

Viewed from an eighth vantage point, it is an object of provide a filtered needle for use with the system of the present invention.

These and other objects were made manifest when considering the following detailed specification when taken into conjunction with the appended drawing figures.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a perspective view of the ampule according to the present invention showing an open orifice and ready for accepting medication.

Figure 2A is a perspective view of the ampule of figure 1 having free flow powder or a compressed tablet of medication inserted therein.

Figure 2B shows the ampule of figure 2A with the orifice closed.

Figure 3 shows a vial described in U.S.P. No. 5,716,346 and the syringe in predocking orientation where a coupler associated with the vial will be in frictional engagement with a coupler associated with the syringe. A plunger of the syringe is nested within the syringe's body.

Figure 3A details the syringe luer.

Figure 4 shows an ampule's contents about to be transferred to the syringe which now has its associated plunger in an extended, deployed configuration and ready to transfer the fluid received from the figure 3 vial into the figure 4 ampule containing the powder or tablet contents.

Figure 5 shows a sectional view of a leading portion of the syringe of figure 4 engaged with the ampule after having dispensed the fluid into the ampule so as to dissolve the powder or tablet contents therein.

Figure 5A details the converging opening of the ampule body.

Figure 5B details the diverging opening of the ampule cap.

Figure 6 shows a sectional view of the syringe just after drawing up the solution made from the fluid and dissolved powder or tablet and after the side walls of the ampule are collapsing. The ampule has been separated from the syringe after fluid extraction.

Figure 7 shows the syringe ready for reception of a needle for injection into the patient or for insertion into the female luer inlet of a catheter.

Figure 8 shows a filter cartridge (with partial fragmentation) of the present invention.

Figure 9 shows a filtered needle for use with the present invention.

Figure 10 shows a filtered needle for use with the present invention.

DESCRIPTION OF PREFERRED EMBODIMENTS

Considering the drawings, wherein like reference numerals denote like parts throughout the various drawing figures, reference numeral 10 is directed to the ampule according to the present invention.

In its essence, and viewing figure 4, the ampule 10 is formed from two parts: a body portion 20 and a cap portion 40. An area of transition noted as a scoreline 30 serves as an area of demarcation between the cap 40 and body 20. The scoreline 30 allows the cap 40 to be dissociated from the body 20 so that the body 20 can dock with a syringe S as shown in figure 5 for filling the body 20 with the solution necessary to dissolve the powder 100 within the ampule 10 and subsequently refilling the syringe S with fluid F containing the now dissolved powder 100 ready for injection. An opening 12 at the scoreline tightly fits over the syringe's luer.

More specifically, and referring to the drawings in detail, the ampule 10 includes a body 20 having an orifice 1 (figure 1) for permitting the placement of free flow powder 100 or alternatively a compressed tablet 110 (figure 2A). Upon placement of powder 100 or tablet 110 the orifice 1 is hermetically and aseptically sealed forming an end wall 2 that appears as a fan-shaped seam 3. Peripheral side walls 4 have one proximal end coterminous with an outer periphery of the end wall 2 and extends away from the end wall 2 so that a blind bore 6 has been formed within which the powder 100 or tablet 110 is to be stored. As shown, the side walls 4 can be a substantially rectangular prism in shape, see figure 2B.

Typically, dry powders and tablets such as a pharmaceutical drug or other medicaments can be stored within the blind bore 6. A distal end of the side wall 4 remote from the end wall 2 is provided with a slight tapering section 8 which

converges towards a longitudinal axis L of the ampule 10 defining a converging end of the ampule 10. This tapering section 8 converges to an opening 12 (figure 5A), or outlet and thereafter communicates with the cap 40. The opening 12 defines a coupler of the ampule 10. The area of transition where the opening 12 is located is preferably coincident with the scoreline 30 to facilitate fracture of the ampule 10 precisely at the opening 12. Thus, the cap 40 can be separated from the body 20.

The cap 40 includes a flag type tab 42 on an exterior surface thereof upon which is printed the product contained within the ampule 10. The tab 42 is shown having a substantially rectangular, planar configuration to provide an exposed surface sufficient to place the name of the product on the tab. The tab 42 also serves as a purchase area to allow a person to grasp the cap 40 so that a twisting motion of the cap 40 with respect to the body 20 will cause severing of the body 20 from the cap 40 at the scoreline 30.

The cap 40 also includes an interior passageway 44 having a diverging contour (figure 5B) which substantially mirrors the slope of the tapered section 8 of the body 20 of the ampule 10 about an axis of symmetry coincident with the scoreline 30. This diverging passageway 44 extends a short distance within the cap 40 for purposes to be assigned.

As shown in figure 4, prior to docking with the syringe S (or needleless cannula), the cap 40 will have been removed from the body 20 of the ampule 10. This allows the opening 12 of the body 20 to be exposed. The opening 12 has an inner peripheral dimension complementary to an exterior diameter of a male luer coupling M found on the syringe's or cannula's outlet. This coupling M defines an opening which forms a coupler of the syringe. Typically, this luer-type connection

tapers and diverges as it approaches a cylindrical hollow H of the syringe S. (See figure 3A.) The luer may include a collar with an internal thread T.

For a friction fit, and with respect to the syringe S shown in figures 5 and 7, the taper of the luer M traditionally couples to a needle. Instead, the syringe docks with the ampule 10 as shown in figure 5 such that the "male" conical taper of luer coupling M of the syringe S passes within the female opening 12 of the body 20 and becomes frictionally engaged at the opening 12, extending into the tapering section 8 of the ampule's body 20. Note that the plunger P on the syringe S (Figure 5) is in a contracted position such that the syringe's cylindrical hollow H, located on an interior portion of the syringe S has received the plunger P to its entire extent and the push rod of the plunger P is in a position immediately adjacent to the cylindrical barrel of the syringe S. In other words, the syringe S is empty and the ampule 10 is already filled with the syringe's liquid.

With respect to figure 6, it should be noted that the side walls 4 of the ampule 10 are formed from a material having the ability to elastically deform in the presence of force. In other words, the side walls 4 of the body of the ampule 10 can collapse. In this way, fluid F contained within the ampule 10 can be transferred back into the syringe S after mixing with the dry contents of the ampule. It is contemplated that one of three methods could be used to transfer the fluid F of the ampule 10 into the syringe S. Assume the syringe and ampule of figure 6 are coupled as in figure 5.

One scenario envisions the ampule 10 being deformed by providing external force in the direction of the arrows D along the outer periphery of the side walls 4. This causes the incompressible fluid F to be forced from the ampule 10 and into the

syringe S. The plunger P will now be forced by fluidic pressure, induced from the ampule 10, to move the plunger P from a first contracted position to a second filled position. The cylindrical hollow H of the syringe S receives the fluid F. In other words, the syringe S will now have been filled with the fluid F and the plunger P will have been extended to a second position for delivery to a patient.

A second scenario, figure 6, involves docking the syringe S or needleless cannula with the ampule 10 as described above. Rather than exerting force D on the ampule 10, instead the plunger P is pulled in the direction of the arrow A which causes negative pressure to exist in the cylindrical hollow H of the syringe S. Since the side walls 4 of the ampule 10 are elastically deformable, the pressure induced by pulling the plunger P in the direction of the arrow A will cause the fluid F within the ampule 10 to migrate into the cylindrical hollow H of the syringe S, filling the syringe S and collapsing the walls 4.

A third scenario involves a hybridization of the first two mentioned techniques. Namely, force D on the exterior side walls 4 of the ampule 10 will be coupled in concert with pulling of the plunger P in the direction of the arrow A so that the incompressible fluid F will have migrated from the ampule 10 to the syringe S.

Figure 7 is directed to a final manipulation of the components according to the present invention. The syringe S is placed in axial registry with the long axis needle N for injection into the patient. In this way, after the syringe S is loaded and ready for subsequent use, the contents of the fluid F within the syringe S will be ready for dispensing the medication to the patient. Different fluids can be pre-loaded into several syringes in a secure area. The healthcare professional can

merely take a collection of the syringes or needleless cannulas to the site for ultimate medicating without having to use a drug preparation cart as is commonly in vogue today. The second variation suggests docking with a catheter inlet I.

Figure 8 shows a filter cartridge 80 that is part of the present invention. The filter cartridge 80 has a filter 82 interiorly located (shown through a fragmentation of the wall of cartridge 80) to remove non-dissolved matter prior to the transfer of the solution to an end user. The cartridge 80 has a female luer-type tapered opening 84 at one extremity adapted to receive a complimentary male luer-type coupling either from a needleless syringe or cannula. In a spaced relationship at a remote extremity to opening 84, is a male luer-type tapered opening 86 adapted to be received a complimentary female luer-type coupling either from a needle or cannula or the like. Furthermore, the filter cartridge 80 could be integral with the ampule 10. The filter cartridge 80 is to be utilized preferably within the present invention after a liquid has been mixed with dry material to remove particulates.

Figure 9 shows a filtering needle 90 that can be used within the system of the present invention. The filtering needle 90 contains a filter 92 to filter out particulate matter prior to it passing through the hypodermic needle N shown in figure 9. There is also shown a female luer-type tapered opening 94 for complimentary reception of a male luer-type coupling from the syringe.

As had been mentioned briefly hereinabove, many people residing in hospitals as in-patients have infusion catheters operatively coupled at all times during their stay. Many of the infusion catheters include a female luer coupling (figure 7) compatible to the contour of syringe S. When this is the case, the syringe S never needs to include a needle on the male luer coupling M. Instead, one can

administer the medicine directly into the infusion catheter via the catheter inlet I. In this way, the number of instances where trained medical personnel are exposed to administering fluids with hypodermic needles will be minimal. This reduces the amount of time and care required in the efficient performance of their tasks and minimizes both occasions for needle sticks and problems of needle disposal.

In use and operation, the syringe S of figure 3 docks with the vial described in U.S.P. No. 5,716,346 to fill the syringe with liquid. Next the ampule 10 of figure 4 is opened by removing cap 40. Syringe S docks with ampule 10 (figure 5). The contents of the syringe enter the ampule. The contents are mixed (preferably with the syringe still attached), dissolving the dry matter of the ampule with the liquid from the syringe. The syringe, still docked to the ampule is then loaded with the liquid mixture. Optionally, the filter 80 may be initially interposed between the ampule 10 and syringe S or subsequently between the syringe and a conventional needle or catheter inlet I. When drawing the liquid through the filter, undissolved matter is entrained in the filter 82. The syringe is then ready for use.

Moreover, having thus described the invention, it should be apparent that numerous structural modifications and adaptations may be resorted to without departing from the scope and fair meaning of the instant invention as set forth hereinabove and as defined hereinbelow by the claims.

CLAIMS

I Claim:

Claim 1 - A method for dissolving a powdery substance stored in an ampule having a first coupler defining the outlet and which has been sealed by occluding the first coupler outlet with a first cap, where a needleless syringe or cannula is configured with a second coupler and an opening which communicates within an interior cylindrical hollow of the syringe so that fluid passes by the second coupler through the opening and into the cylindrical hollow and fills the syringe or cannula, the steps including:

providing a vial which has been filled with a fluid, which has a vial outlet including a third coupler defining the vial outlet and which has been sealed by occluding the third coupler of the vial outlet with a second cap;

subsequently removing the second cap from the vial;

orienting the second and third couplers of the syringe or cannula and vial, respectively into complementary, fluid-tight locking engagement so that the opening of the vial registers with the opening of the syringe or cannula;

transferring the contents of the vial to the syringe or cannula;

subsequently removing the first cap from the ampule;

orienting the first coupler of the ampule with second coupler of the syringe or cannula into complementary, fluid-tight locking engagement so that the opening of the ampule registers with the opening of the syringe or cannula;

transferring the fluid of the syringe into the ampule;

mixing the powdery substance and fluid until the powdery substance is dissolved thus making a mixture while the ampule and syringe or cannula remain mated;

conveying the mixture back into the syringe or cannula; and

preparing the syringe or cannula for the capability of inserting the mixture into an animate or inanimate object.

Claim 2 - The method of claim 1 wherein transferring the contents from the vial includes the steps of compressing walls of the vial after the second and third couplers are docked in complementary fluid tight locking engagement,

whereby an increase in fluid pressure from compressing walls of the vial forces fluid out of the vial.

Claim 3 - The method of claim 1 wherein conveying the contents from the ampule back to the syringe or cannula includes the steps of compressing walls of the vial after the first and second couplers are docked in complementary fluid tight locking engagement,

whereby an increase in fluid pressure from compressing walls of the vial forces fluid out of the vial.

Claim 4 - The method of claim 2 wherein conveying the contents from the ampule back to the syringe or cannula includes the steps of compressing walls of the vial after the first and second couplers are docked in complementary fluid tight locking engagement,

whereby an increase in fluid pressure from compressing walls of the vial forces fluid out of the vial.

Claim 5 - The method of claim 1 wherein said transferring step includes retracting a plunger which had been housed within the cylindrical hollow of the syringe so that the plunger retraction creates a negative pressure in the syringe which is transferred into the vial so that fluid within the vial is drawn into the syringe while collapsing walls of the vial.

Claim 6 - The method of claim 1 wherein said conveying step includes retracting a plunger which had been housed within the cylindrical hollow of the syringe so that the plunger retraction creates a negative pressure in the syringe which is transferred into the vial so that fluid within the vial is drawn into the syringe while collapsing walls of the vial.

Claim 7 - The method of claim 5 wherein said conveying step includes retracting a plunger which had been housed within the cylindrical hollow of the syringe so that the plunger retraction creates a negative pressure in the syringe which is transferred into the vial so that fluid within the vial is drawn into the syringe while collapsing walls of the vial.

Claim 8 - The method of claim 1 including dissociating the first and second couplers after the mixture in the ampule has been transferred to the syringe or cannula and taking the cap from the vial and sealing the second coupler of the syringe with the cap from the vial or ampule.

Claim 9 - The method of claim 2 including dissociating the first and second couplers after the mixture in the ampule has been transferred to the syringe or cannula and taking the cap from the vial and sealing the second coupler of the syringe with the cap from the vial or ampule.

Claim 10 - The method of claim 5 including dissociating the first and second couplers after the mixture in the ampule has been transferred to the syringe or cannula and taking the cap from the vial and sealing the second coupler of the syringe with the cap from the vial or ampule.

Claim 11 - The method of claim 3 including dissociating the first and second couplers after the mixture of the ampule has been transferred to the syringe or cannula and taking the cap from the vial and sealing the second coupler of the syringe with the cap from the vial or ampule.

Claim 12 - The method of claim 6 including dissociating the first and second couplers after the mixture of the ampule has been transferred to the syringe or cannula and taking the cap from the vial and sealing the second coupler of the syringe with the cap from the vial or ampule.

Claim 13 - The method of claim 1 including standing the filled syringe on the cap.

Claim 14 - A method for forming an ampule to transfer pharmaceutical grade fluid or solid to be administered, the steps including:

forming an ampule with resilient walls so that the ampule can be collapsed and creating an orifice to pass the pharmaceutical grade fluid or solid;

forming an opening on the ampule such that the opening is circumscribed by a coupler which is to be complementally fastened to receive a dose administering device;

filling the ampule with the pharmaceutical grade fluid or solid; and
sealing the ampule.

Claim 15 - The method of claim 14 including sterilizing the pharmaceutical grade fluid and the ampule.

Claim 16 - The method of claim 14 including providing a scoreline at the opening of the ampule which has been occluded by capping the ampule opening so that the opening and the contents of the ampule can be accessed by severing the cap from the ampule at the scoreline.

Claim 17 - The method of claim 16 including after filling the ampule with pharmaceutical fluid making the ampule with an end wall and side walls with the side walls extending from the end wall to define a blind bore and making the side walls of the ampule resilient so that the side walls can be distorted to force the fluid within the ampule out of the opening once the cap has been severed.

Claim 18 - The method of claim 17 including forming the cap on the ampule with an interior passageway having a dimension complementary to an outlet of a syringe or needleless cannula for frictional engagement thereover after having transferred a mixture from the ampule to the syringe or needleless cannula.

Claim 19 - The method of claim 18 further including providing a diverging portion on the ampule immediately adjacent its opening so that a luer-type taper on the syringe or cannula can be used to frictionally reside within the ampule for docking when transferring fluid from the ampule to the syringe or cannula.

Claim 20 - The method of claim 19 including providing a tab surface on the cap and including indicia on the tab correlative of the mixture within the ampule to provide an indicator of the contents within the ampule.

Claim 21 - The method of claim 16 including forming the cap on the ampule with an interior passageway having a dimension complementary to an outlet of a

syringe or cannula for frictional engagement thereover after having transferred a mixture from the ampule to the syringe or cannula.

Claim 22 - The method of claim 14 further providing a diverging portion on the ampule immediately adjacent its opening so that a luer-type taper on the syringe or cannula can be used to frictionally reside within the ampule for docking when transferring a mixture from the ampule to the syringe or cannula.

Claim 23 - The method of claim 16 including providing a tab surface on the cap and including indicia on the tab correlative of a mixture within the ampule to provide an indicator of the contents within the ampule.

Claim 24 - A needleless dosage transfer system, for removing a sterile pharmaceutical grade fluid from a sealed ampule to a needleless syringe or needleless cannula, comprising in combination,

an ampule defined by an end and collapsible side walls extending from said end thereby defining a blind bore and an open end,

said side walls formed from resilient, collapsible material,

a coupler at said open end of said vial, and a removable cap occluding said open end,

said coupler configured and provided with means to connect to an opening of the syringe or cannula in fluid communication therewith, whereby fluid can be directly transferred from the ampule without an interconnecting needle after removing said cap and coupling said opening to the needleless syringe or cannula.

Claim 25 - The system of claim 24 wherein said coupler at said open end of said ampule includes a converging portion as it extends from said ampule to said coupler open end.

Claim 26 - The system of claim 24 wherein said opened end is integrally formed with said cap and is dissociated from said removable cap by means of a scoreline formed on said ampule associated at said opening.

Claim 27 - The system of claim 26 wherein said removable cap includes an interior passageway having a diverging passageway substantially symmetrical to the said converging portion of said ampule adjacent said opening so that an axis of symmetry is provided at said scoreline with respect to said converging and diverging portions.

Claim 28 - The system of claim 24 wherein said cap includes indicia means on an exterior surface thereof correlative with the fluid within said ampule.

Claim 29 - The system of claim 27 wherein said passageway of said removable cap is dimensioned to frictionally override an opening of said needleless syringe or cannula which had been used to receive the fluid from the ampule whereby indicia on said removable cap travels with the needleless syringe or cannula correlative of the fluid within said syringe which heretofore had been in said ampule.

Claim 30 - The system of claim 24 wherein said cap includes a foot with facets at a perimeter thereof which provides a sterile support and prevents rolling of said cap and any devices connected thereto when placed horizontally on a flat surface.

Claim 31 - An ampule for storing a pharmaceutical product in a manner to inhibit lability of the product and permitting the transfer of the product in an aseptic manner to avoid nosocomial infection from ambient air comprising:

resilient walls that can be collapsed and creating an orifice to pass a pharmaceutical grade fluid or solid therethrough;

an opening on said ampule whereby the opening is circumscribed by a coupler which is to be complementally fastened to receive a dose administering device.

Claim 32 - The ampule of claim 31 further including a cap for occluding said opening.

Claim 33 - The ampule of claim 32 further providing a scoreline proximate said opening whereby any contents within said ampule can be accessed by severing said cap for said ampule at said scoreline.

Claim 34- The ampule of claim 31 whereupon after passing a pharmaceutical grade fluid or solid through said orifice, sealing the orifice to form an end wall whereby said side walls extend from said end wall to define a blind bore and making said side walls so that said side walls can be distorted to force said fluid or solid within the ampule out said opening once said cap has been severed.

Claim 35 - The ampule of claim 32 whereby said cap is formed with an interior passageway having a dimension complementary to an outlet of a syringe or cannula for frictional engagement thereover after having transferred a mixture from said ampule to a syringe or cannula.

Claim 36 - The ampule of claim 31 wherein said cap has a tab surface.

Claim 37 - The ampule of claim 36 wherein said tab surface includes indicia thereon correlative of a mixture within the ampule.

Claim 38 - The ampule of claim 37 wherein said indicia provides an indicator of the contents within the ampule.

~~Claim 39~~ - A filter cartridge of an ampule comprising:

a body having first and second coupling-ends and a filter disposed therebetween;

whereby said first coupling-end includes a female luer-type tapering for frictional engagement with a needleless syringe or cannula; and

whereby said second coupling-end includes a male luer-type tapering for frictional engagement with a female luer-type taper on a needle or cannula.

Claim 40 - The filter cartridge of claim 39 integral with an ampule for storing a pharmaceutical product in a manner to inhibit lability of the product and permitting the transfer of the product in an aseptic manner to avoid nosocomial infection from ambient air comprising:

resilient walls that can be collapsed and creating an orifice to pass a pharmaceutical grade fluid or solid therethrough;

an opening on said ampule whereby the opening is circumscribed by a coupler which is to be complementally fastened to receive a dose administering device.

Claim 41 - The system of claim 24 including a filtered needle.

Claim 42 - The system of claim 25 including a filtered needle.

Claim 43 - The system of claim 26 including a filtered needle.

Claim 44 - The system of claim 27 including a filtered needle.

Claim 45 - The system of claim 28 including a filtered needle.

Claim 46 - The system of claim 29 including a filtered needle.

Claim 47 - The system of claim 30 including a filtered needle.

ABSTRACT OF THE DISCLOSURE

A method and an apparatus for the storage and transfer of a lyophilisate is disclosed. An ampule prior to its sealment has an orifice at one end for the addition of the lyophilisate. The ampule has a body portion formed with flexibly deformable walls and defines a blind bore. After placement of the lyophilisate, the orifice is closed. An opening of the ampule is also included and has a tapered section adapted to frictionally fit over a taper of a male luer-type fitting commonly found on syringes and needleless cannulas. The opening is protected by a frangible cap integrally formed during manufacture. By removing the cap and docking the opening with a syringe, liquid enters the ampule for mixing with the dry contents in the ampule. After mixing the solution is removed by deforming the walls of the ampule. Fluid is forced from the ampule opening into a syringe. The opening of the ampule is protected with the cap that includes a scoreline which, when fractured, defines the opening. The cap to be removed from the ampule prior to its use is fabricated as one piece with the ampule preferably using a blow, fill, seal or injection molding technique in order to assure sterile conditions during manufacture and filling. A tab is associated with the cap which lists the ingredients within the ampule. The ampule also supports an area which lists the ampule's contents. The cap is specifically structured with a coupling so that after its removal from the ampule, it can frictionally engage the luer opening of the syringe or cannula. The tab provides indicia thereon as to the contents within the thus loaded syringe and to temporarily seal the syringe or cannula. The disclosed needleless dosage transfer system for filling medicating devices such as syringes or needleless




FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3




FIGURE 3A




FIGURE 5



FIGURE 5A




FIGURE 5B




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Method and Apparatus for the Storage and Transfer of a Lyophilisate, the specification of which:

XX is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37. (Code of Federal Regulations 1.56(a)).

I hereby claim foreign priority benefits under Title 35, U.S. Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed
			N O
(Number)	(Country)	(Day/Month/Year)	

I hereby claim the benefit under Title 35, U.S. Code 120 of any U.S. application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior U.S. application in the manner provided by the first paragraph of Title 35, U.S. Code 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status-patented, pending, abandoned)
--------------------------	---------------	---------------------------------------

I hereby appoint BERNHARD KRETEN, Reg. No. 27,037 to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

Address all telephone calls to: (916) 921-6181

Address all correspondence to 77 Cadillac Drive, Suite 245, Sacramento, California 95825

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Barry Farris Citizenship: United States

Inventor's Signature: _____ Date: _____

Residence: Post Office Box 1817, Zephyr Cove, Nevada 89948

Post Office Address: Post Office Box 1817, Zephyr Cove, Nevada 89948